Coronavirus: Oxford vaccine ‘may be rolled out within weeks’ - but UK faces jab shortages
Mass production difficulties will limit early supplies

A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
Two Covid-19 vaccines are on the verge of being certified as safe and effective - but production delays mean the first batches may reach no more than a fraction of the UK population.
A homegrown vaccine, developed by Oxford University and manufactured by AstraZeneca, has the “possibility of being ready before the end of the year”, according to Kate Bingham, the chair of the government’s vaccine task force.
She told MPs yesterday that the first three batches of the drug, now in production, “should get us up to about four million doses by the end of the year”. But as The Telegraph points out, the government pledged in May that “30 million vaccines would be ready by September to allow for immediate mass deployment if trials were successful”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The delay is down to the technical challenge of splicing an immunity-generating protein from the coronavirus with a harmless chimpanzee virus that will carry it into human cells.
“It’s not through lack of care and attention or availability of equipment or anything like that,” Bingham said. “It’s just that this normally takes a very long time.”
Another potential vaccine, developed in Germany by Pfizer and BioNTech, is simpler to manufacture but “contains a type of genetic material known as mRNA that must be stored at minus 70C”, The Times reports. That makes it difficult and expensive to distribute.
The UK has signed deals to buy 350 million doses of a total of six vaccines, all of which are undergoing trials. Once the results are published, the government’s health authorities will decide whether to approve their widespread use.
“The US regulator, the Food and Drug Administration, has said it wanted at least 50% efficacy to approve a vaccine,” The Guardian reports. “But if one was found to prevent 40% of cases, [UK] policymakers would have to consider whether it would be of help to the NHS.”
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Why the Roman Empire is suddenly everywhere online
The Explainer It fell more than 1,500 years ago — so why is it dominating social media?
By Justin Klawans Published
-
How climate change is going to change the insurance industry
The Explainer Some regions will soon be 'uninsurable'
By Devika Rao Published
-
TV to watch in October, from 'Loki' to 'The Fall of the House of Usher'
The Explainer Celebrate spooky season with some eerie streaming shows
By Brendan Morrow Published
-
Rishi Sunak's tree code: what is the PM's election strategy?
Today's Big Question Conservative leader lining up major policy announcements in bid to rebrand as 'change' candidate
By Elliott Goat Published
-
Will Rishi Sunak's green wedge issue win over the public?
Today's Big Question The PM draws dividing line with Labour on net zero ahead of the next general election
By Sorcha Bradley Published
-
Industry backlash as Sunak set to water down green pledges
Speed Read Automotive and energy bosses look for clarity after PM backs away from UK net zero goal
By Arion McNicoll Published
-
October by-elections: what's at stake for Labour, Lib Dems and Tories
Parties will contest two former safe Tory seats on 19 October, putting pressure on Rishi Sunak
By Harriet Marsden Published
-
Jobs for the boys: does the UK need a minister for men?
Conservative MP calls for dedicated cabinet role to combat 'crisis' in men's mental health and education
By Harriet Marsden Published
-
Covid inquiry: what we have heard so far
feature Public inquiry hears damning evidence from scientists amid finger-pointing from ministers and civil servants alike
By Arion McNicoll Published
-
Covid inquiry: is the government attempting a cover-up?
Today's Big Question Cabinet Office accused of ‘cowardly’ bid to obstruct the official investigation
By Chas Newkey-Burden Published
-
Covid inquiry: what’s in Boris Johnson’s WhatsApps?
Today's Big Question Former PM set for bitter legal battle after refusing to hand over unredacted pandemic messages and diaries
By The Week Staff Published